Electro-acupuncture combined with adjuvant chemotherapy in gastric cancer (EAGER-2): a protocol for a multicenter randomized controlled trial
The EAGER-2 study is a multicenter, participant-blinded, sham-controlled randomized trial designed to validate the efficacy of electro-acupuncture combined with adjuvant chemotherapy in improving disease-free survival and other clinical outcomes for gastric cancer patients following gastrectomy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine your body is a high-tech fortress that just successfully repelled a massive invasion of cancer cells. The main battle is over, and the enemy has been pushed out. But here's the scary part: tiny, invisible spies might still be hiding in the walls, waiting to spring a surprise attack later. This is what happens after surgery for gastric (stomach) cancer. Even after the tumor is gone, these "spies" can cause the cancer to come back (recur) or spread (metastasize).
Right now, the standard defense plan involves a powerful chemical shield called chemotherapy. Doctors give this shield for a while to try to wipe out any remaining spies. But here's the catch: even with this strong shield, the spies sometimes still win. In fact, for many patients, the cancer returns within a few years, and the current "super-weapon" of adding immune-boosting drugs (like checkpoint inhibitors) doesn't always help unless the patient had them before surgery.
So, scientists are looking for a secret weapon to strengthen the fortress walls and keep those spies away for good. Enter Electro-acupuncture.
Think of electro-acupuncture not as magic, but as a sophisticated tuning system for your body's internal radio. It uses tiny, sterile needles (like fine wires) placed at specific "stations" on your body's energy map. Once the needles are in, a gentle electrical pulse zaps through them, like a soft, rhythmic drumbeat that wakes up your immune system and calms down the inflammation that helps cancer grow.
The Big Question:
Does this "tuning" actually work to keep the cancer away longer?
A previous study (called the EAGER trial) hinted that it might. They found that patients who got this electrical tuning along with their chemo seemed to stay cancer-free longer—jumping from about 55% staying clear for three years to over 76%. That sounds amazing! But there was a problem: the study didn't have a "fake" group to compare against. Maybe the patients just felt better because they knew they were getting special attention (the placebo effect), or maybe the doctors just checked them more carefully. We didn't know for sure if the needles were the real hero.
The New Mission: EAGER-2
Now, a team of researchers is launching a massive, high-stakes game called EAGER-2. They are gathering 346 patients from over 16 different hospitals across China to settle this mystery once and for all.
Here's how the game works:
- The Players: 346 people who just had stomach cancer surgery and are about to start their standard chemotherapy.
- The Teams: They are split into two teams.
- Team Real: Gets the actual electro-acupuncture. They get needles placed at 8 specific spots (like a map of the stomach, spine, and legs) and get a gentle electrical buzz for 30 minutes.
- Team Fake (Sham): Gets a "placebo" treatment. They get the same amount of time, the same friendly attention, and they see the same needles and lights. But, the needles are blunt and don't actually poke the skin, and the electrical machine is turned off (or set to a channel that does nothing). They are placed on spots that aren't real acupuncture points.
- The Blinding: The patients don't know which team they are on. The doctors checking the results don't know either. This is crucial to make sure the results are fair.
- The Schedule: Both teams get their treatment once a week, three times during every chemotherapy cycle, for the first four cycles.
What Are They Measuring?
The main goal isn't just how the patients feel (though that's important too); it's Disease-Free Survival (DFS). This is a stopwatch that starts the moment the surgery is done. It stops the second the cancer comes back, spreads, or if the patient passes away from any cause. The researchers want to see if Team Real keeps the stopwatch running longer than Team Fake.
They are also checking:
- Quality of Life: Using a special scorecard (FACT-Ga) to see if patients feel less tired, less nauseous, and happier.
- Symptom Burden: Tracking pain, anxiety, and other icky feelings using a scale called mESAS.
- Traditional Symptoms: Checking for specific feelings that Traditional Chinese Medicine tracks, like digestion issues.
- Survival: How long patients live overall (up to 5 years).
The Rules of the Game
The researchers are being super strict to make sure the data is real.
- They are looking at 346 people because math says they need that many to be 85% sure they can spot a real difference if one exists.
- They are following a strict schedule: CT scans every 3 months for the first 3 years, then every 6 months, to catch any returning spies early.
- If a patient gets really sick from the chemo (Grade 3-4 side effects), the doctors can stop the study for that person to keep them safe.
Why This Matters
If this study proves that the "tuning" works, it could change the rules of the game for stomach cancer. It would mean that adding these gentle, electrical needle treatments to the standard chemo could be a powerful way to stop the cancer from coming back, giving patients a much longer chance at a cancer-free life.
But until the study is done and the data is in, we have to be patient. The previous study suggested it worked, but this new one is designed to prove it. It's like having a really good hunch that a new key opens a door, but you need to try it on the lock with a blindfold on to be 100% sure it's the right key.
The study is currently recruiting, and the clock is ticking on the stopwatch for those 346 brave participants. If the results are positive, it could be a huge win for everyone fighting gastric cancer. If not, we'll know that this particular key doesn't fit this lock, and scientists will have to keep looking for the right one.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.